Vector Science and Therapeutics (TSXV:PAIN) Stock Based Compensation: C$1.19 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
15 GF Score
Price C$2.00
View Full Analysis

What is Vector Science and Therapeutics Stock Based Compensation?

Vector Science and Therapeutics TSXV:PAIN -4.31% 15 Stock Based Compensation is C$1.19 Mil as of May. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 15/100.

Vector Science and Therapeutics's Stock Based Compensation for the three months ended in May. 2026 was C$0.93 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 was C$1.19 Mil.

Vector Science and Therapeutics Stock Based Compensation Related Terms

Vector Science and Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics Stock Based Compensation Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
Stock Based Compensation
0.00 0.00

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26 May26
Stock Based Compensation Get a 7-Day Free Trial 0.00 0.00 0.26 0.00 0.93
TSXV:PAIN
15GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.19 Mil.

What does a Stock Based Compensation of C$1.19 Mil mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Stock Based Compensation of C$1.19 Mil as of May. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' Stock Based Compensation too high?
Vector Science and Therapeutics' current Stock Based Compensation is C$1.19 Mil. Overall, Vector Science and Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Stock Based Compensation compare to ABT and SYK?
Vector Science and Therapeutics' Stock Based Compensation of C$1.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current Stock Based Compensation is C$1.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Stock Based Compensation of C$1.19 Mil. The current Stock Based Compensation is C$1.19 Mil. Vector Science and Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Stock Based Compensation is C$1.19 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
15GF Score

Get the complete analysis for TSXV:PAIN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.00
Price